FIELD: biotechnology.
SUBSTANCE: invention relates to the field of fusion proteins for serine proteases inhibition, and can be used in medicine. Fusion proteins having at least one human alpha-1 antitrypsin (AAT) polypeptide operably linked to an immunoglobulin Fc polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:6 are obtained.
EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.
18 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2727452C1 |
| FUSION POLYPEPTIDE CONTAINING WAP DOMAIN AND THEIR APPLICATION METHODS | 2012 |
|
RU2639526C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| POLYPEPTIDES | 2011 |
|
RU2577964C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF FUNCTIONAL FRAGMENT OF HUMAN IL-1RA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2023 |
|
RU2821896C1 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| HOMODIMERIC FUSED PROTEIN WITH ACTIVITY OF ANGIOGENESIS INHIBITOR (VARIANTS), DNA MOLECULE ENCODING HOMODIMERIC FUSED PROTEIN, VECTOR FOR EXPRESSION OF HOMODIMERIC FUSED PROTEIN, METHOD FOR TRANSFECTION OF MAMMALIAN CELL AND METHOD FOR PREPARING HOMODIMERIC FUSED PROTEIN | 1999 |
|
RU2240328C2 |
